At the annual meeting, researchers led by Xenofon Baraliakos, MD, of the Ruhr-University of Bochum in Germany, presented long-term, end-of-study findings from the phase III MEASURE 1 extension trial, which is evaluating the safety and efficacy of secukinumab (SEC) in patients with ankylosing spondylitis (AS).
At the annual meeting, a group of researchers led by Iain B. McInnes, MBChB, MRCP, PhD, of the University of Glasgow in the United Kingdom, presented long-term data from a phase III study evaluating the safety and efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA).
Prior to the start of the annual meeting, an afternoon of presentations focused on “Applications of Mobile Health Technologies.”
A pre-meeting session at the annual meeting delved into the benefits and challenges of “PROMIS Versus Legacy Data Instruments” in collecting patient-reported outcomes (PROs) in rheumatology.
Prior to the annual meeting, the ACR Clinical Research Conference focused on technology advances that are changing the landscape of medicine and rheumatology. Beyond electronic health records, there is a broad range of digital and mobile technologies.
During an afternoon of specialized pre-meeting sessions at the annual meeting, speakers addressed various aspects of health technology. One presenter, Bernard Vrijens, PhD, of AARDEX Group, stressed to attendees that “Medication Adherence Is a Key Element to Integrate in e-Health.”